The renin-angiotensin system in progression, remission and regression of chronic nephropathies

Claudio Aros, Giuseppe Remuzzi

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Chronic proteinuric nephropathies may progress to end-stage renal disease (ESRD) through a series of events relatively independent of the initial insult that causes parenchymal damage when the injury involves a critical number of nephrons. The key event is enhanced glomerular capillary pressure, which, among other effects, impairs glomerular permeability to proteins, which reach the lumen of the proximal tubule. In this pathological process angiotensin II has a central role. Reabsorption of filtered proteins contributes to the interstitial injury by activating intracellular events, including upregulation of vasoactive and inflammatory genes. Both interstitial inflammation and progression of disease can be limited by angiotensin-convetting enzyme (ACE) inhibitors that strengthen the glomerular permeability barrier to proteins, thus limiting proteinuria and filtered protein-dependent inflammatory signals. Clinical evidence suggests that remission is now achievable in some patients with chronic nephropathies. The current lag time between starting treatment and remission, however, is such that a substantial proportion of patients still progress to ESRD before their renal function begins to stabilize. A multimodal approach aimed at reducing or abolishing all the risk factors for progression may shorten the time to remission for the majority of patients with proteinuric nephropathies.

Original languageEnglish
JournalJournal of Hypertension
Volume20
Issue numberSUPPL. 3
DOIs
Publication statusPublished - Jun 2002

Fingerprint

Renin-Angiotensin System
Chronic Kidney Failure
Permeability
Proteins
Nephrons
Angiotensins
Wounds and Injuries
Enzyme Inhibitors
Pathologic Processes
Proteinuria
Angiotensin II
Disease Progression
Up-Regulation
Inflammation
Kidney
Pressure
Genes
Therapeutics

Keywords

  • Chronic nephropathies
  • Renal disease progression
  • Renin-angiotensin system blockade

ASJC Scopus subject areas

  • Endocrinology
  • Internal Medicine

Cite this

The renin-angiotensin system in progression, remission and regression of chronic nephropathies. / Aros, Claudio; Remuzzi, Giuseppe.

In: Journal of Hypertension, Vol. 20, No. SUPPL. 3, 06.2002.

Research output: Contribution to journalArticle

@article{5071746070814c45a96d47ebd26c1ee2,
title = "The renin-angiotensin system in progression, remission and regression of chronic nephropathies",
abstract = "Chronic proteinuric nephropathies may progress to end-stage renal disease (ESRD) through a series of events relatively independent of the initial insult that causes parenchymal damage when the injury involves a critical number of nephrons. The key event is enhanced glomerular capillary pressure, which, among other effects, impairs glomerular permeability to proteins, which reach the lumen of the proximal tubule. In this pathological process angiotensin II has a central role. Reabsorption of filtered proteins contributes to the interstitial injury by activating intracellular events, including upregulation of vasoactive and inflammatory genes. Both interstitial inflammation and progression of disease can be limited by angiotensin-convetting enzyme (ACE) inhibitors that strengthen the glomerular permeability barrier to proteins, thus limiting proteinuria and filtered protein-dependent inflammatory signals. Clinical evidence suggests that remission is now achievable in some patients with chronic nephropathies. The current lag time between starting treatment and remission, however, is such that a substantial proportion of patients still progress to ESRD before their renal function begins to stabilize. A multimodal approach aimed at reducing or abolishing all the risk factors for progression may shorten the time to remission for the majority of patients with proteinuric nephropathies.",
keywords = "Chronic nephropathies, Renal disease progression, Renin-angiotensin system blockade",
author = "Claudio Aros and Giuseppe Remuzzi",
year = "2002",
month = "6",
doi = "10.1097/00004872-200212000-00001",
language = "English",
volume = "20",
journal = "Journal of Hypertension",
issn = "0263-6352",
publisher = "Lippincott Williams and Wilkins",
number = "SUPPL. 3",

}

TY - JOUR

T1 - The renin-angiotensin system in progression, remission and regression of chronic nephropathies

AU - Aros, Claudio

AU - Remuzzi, Giuseppe

PY - 2002/6

Y1 - 2002/6

N2 - Chronic proteinuric nephropathies may progress to end-stage renal disease (ESRD) through a series of events relatively independent of the initial insult that causes parenchymal damage when the injury involves a critical number of nephrons. The key event is enhanced glomerular capillary pressure, which, among other effects, impairs glomerular permeability to proteins, which reach the lumen of the proximal tubule. In this pathological process angiotensin II has a central role. Reabsorption of filtered proteins contributes to the interstitial injury by activating intracellular events, including upregulation of vasoactive and inflammatory genes. Both interstitial inflammation and progression of disease can be limited by angiotensin-convetting enzyme (ACE) inhibitors that strengthen the glomerular permeability barrier to proteins, thus limiting proteinuria and filtered protein-dependent inflammatory signals. Clinical evidence suggests that remission is now achievable in some patients with chronic nephropathies. The current lag time between starting treatment and remission, however, is such that a substantial proportion of patients still progress to ESRD before their renal function begins to stabilize. A multimodal approach aimed at reducing or abolishing all the risk factors for progression may shorten the time to remission for the majority of patients with proteinuric nephropathies.

AB - Chronic proteinuric nephropathies may progress to end-stage renal disease (ESRD) through a series of events relatively independent of the initial insult that causes parenchymal damage when the injury involves a critical number of nephrons. The key event is enhanced glomerular capillary pressure, which, among other effects, impairs glomerular permeability to proteins, which reach the lumen of the proximal tubule. In this pathological process angiotensin II has a central role. Reabsorption of filtered proteins contributes to the interstitial injury by activating intracellular events, including upregulation of vasoactive and inflammatory genes. Both interstitial inflammation and progression of disease can be limited by angiotensin-convetting enzyme (ACE) inhibitors that strengthen the glomerular permeability barrier to proteins, thus limiting proteinuria and filtered protein-dependent inflammatory signals. Clinical evidence suggests that remission is now achievable in some patients with chronic nephropathies. The current lag time between starting treatment and remission, however, is such that a substantial proportion of patients still progress to ESRD before their renal function begins to stabilize. A multimodal approach aimed at reducing or abolishing all the risk factors for progression may shorten the time to remission for the majority of patients with proteinuric nephropathies.

KW - Chronic nephropathies

KW - Renal disease progression

KW - Renin-angiotensin system blockade

UR - http://www.scopus.com/inward/record.url?scp=0036600952&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036600952&partnerID=8YFLogxK

U2 - 10.1097/00004872-200212000-00001

DO - 10.1097/00004872-200212000-00001

M3 - Article

C2 - 12184055

AN - SCOPUS:0036600952

VL - 20

JO - Journal of Hypertension

JF - Journal of Hypertension

SN - 0263-6352

IS - SUPPL. 3

ER -